Incyte Guidance Showed $680M Shortfall, Royalty Adjustment Brings 11.5% Growth
Incyte’s shares dropped 8.2% after its 2026 revenue guidance appeared $680 million below consensus due to a royalties accounting technicality. Adjusted for those royalties, 2026 net product sales guidance implies 11.5% year-over-year growth and strong gains in the ex-Jakafi portfolio, supporting a bullish long-term outlook.
1. Guidance Miss and Royalty Accounting Nuance
Incyte reported that its initial 2026 revenue guidance appeared $680 million below consensus, triggering an 8.2% share price decline. This variance stemmed from an accounting change that shifted royalty revenues out of the primary sales line, creating an apparent shortfall.
2. Adjusted Sales Guidance and Growth Projection
When royalty adjustments are included, Incyte’s 2026 net product sales guidance aligns closely with analyst expectations and reflects 11.5% year-over-year growth. Jakafi remains the largest contributor, with royalties now reported separately to enhance transparency.
3. Ex-Jakafi Portfolio and Future Outlook
Sales guidance for Opzelura was marginally below consensus, but the ex-Jakafi portfolio—driven by expanding interleukin-23 inhibitors and topical therapies—continues rapid expansion. Management highlights strong mid-teens growth potential beyond 2026, underpinning a robust long-term revenue trajectory.